Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Therapies involving bone-marrow-derived mesenchymal stem cells (BM-MSCs) have considerable potential in the management of hepatic disease. BM-MSCs have been investigated in regenerative medicine due to their ability to secrete various growth factors and cytokines that regress hepatic fibrosis and enhance hepatocyte functionality. The aim of this study was to determine the antifibrosis effect of BM-MSCs on activated hepatic stellate cells (HSCs) and the mechanism underlying how BM-MSCs modulate the function of activated HSCs. Methods: We used HSCs in both direct and indirect co-culture systems with BM-MSCs to evaluate the antifibrosis effect of BM-MSCs. The cell viability and apoptosis were evaluated by a direct co-culture system of activated HSCs with BM-MSCs. The activations of both HSCs alone and HSCs with BM-MSCs in the direct co-culture system were observed by immunocytochemistry for alpha-smooth muscle actin (α-SMA). The levels of growth factors and cytokines were evaluated by an indirect co-culture system of activated HSCs with BM-MSCs. Results: The BM-MSCs in the direct co-culture system significantly decreased the production of α-SMA and the viability of activated HSCs, whereas they induced the apoptosis of activated HSCs. The BM-MSCs in the indirect co-culture system decreased the production of transforming growth factor-β1 and interleukin (IL)-6, whereas they increased the production of hepatocyte growth factor and IL-10. These results confirmed that the juxtacrine and paracrine effects of BM-MSCs can inhibit the proliferative, fibrogenic function of activated HSCs and have the potential to reverse the fibrotic process by inhibiting the production of α-SMA and inducing the apoptosis of HSCs. Conclusions: These results have demonstrated that BM-MSCs may exert an antifibrosis effect by modulating the function of activated HSCs. (Clin Mol Hepatol 2015;21:141-149)
Abstract
Background/Aims: Therapies involving bone-marrow-derived mesenchymal stem cells (BM-MSCs) have considerable potential in the management of hepatic disease. BM-MSCs have been investigated in regenerative medicine due to their ability to secrete various growth factors and cytokines that regress hepatic fibrosis and enhance hepatocyte functionality. The aim of this study was to determine the antifibrosis effect of BM-MSCs on activated hepatic stellate cells (HSCs) and the mechanism underlying how BM-MSCs modulate the function of activated HSCs. Methods: We used HSCs in both direct and indirect co-culture systems with BM-MSCs to evaluate the antifibrosis effect of BM-MSCs. The cell viability and apoptosis were evaluated by a direct co-culture system of activated HSCs with BM-MSCs. The activations of both HSCs alone and HSCs with BM-MSCs in the direct co-culture system were observed by immunocytochemistry for alpha-smooth muscle actin (α-SMA). The levels of growth factors and cytokines were evaluated by an indirect co-culture system of activated HSCs with BM-MSCs. Results: The BM-MSCs in the direct co-culture system significantly decreased the production of α-SMA and the viability of activated HSCs, whereas they induced the apoptosis of activated HSCs. The BM-MSCs in the indirect co-culture system decreased the production of transforming growth factor-β1 and interleukin (IL)-6, whereas they increased the production of hepatocyte growth factor and IL-10. These results confirmed that the juxtacrine and paracrine effects of BM-MSCs can inhibit the proliferative, fibrogenic function of activated HSCs and have the potential to reverse the fibrotic process by inhibiting the production of α-SMA and inducing the apoptosis of HSCs. Conclusions: These results have demonstrated that BM-MSCs may exert an antifibrosis effect by modulating the function of activated HSCs. (Clin Mol Hepatol 2015;21:141-149)
참고문헌 (33)
- Schiff ER, "Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B", Clin Gastroenterol Hepatol, 9, pp.274~276 (2011)
- Chang TT, "Long-term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
- Kim MY, "Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis", Eur J Gastroenterol Hepatol, 21, pp.1241~1246 (2009)
- Kim MY, "Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis", Hepatology, 56, pp.1053~1062 (2012)
- Geerts A., "History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells", Semin Liver Dis, 21, pp.311~335 (2001)
- Bataller R, "Hepatic stellate cells as a target for the treatment of liver fibrosis", Semin Liver Dis, 21, pp.437~451 (2001)
- Knittel T, "Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers : distinct roles of(myo-)fibroblast subpopulations in hepatic tissue repair", Histochemistry and cell biology, 112, pp.387~401 (1999)
- Bataller R, "Liver fibrosis", J Clin Invest, 115, pp.209~218 (2005)
- El-Lakkany NM, "Anti-inflammatory", anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis, 2012, pp.5, 9~
- Kharaziha P, "Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection : a phase I-II clinical trial", Eur J Gastroenterol Hepatol, 21, pp.1199~1205 (2009)
- Pai M, "Autologous infusion of expanded mobilized adult bone marrowderived CD34+ cells into patients with alcoholic liver cirrhosis", Am J Gastroenterol, 103, pp.1952~1958 (2008)
- Terai S, "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy", Stem cells, 24, pp.2292~2298 (2006)
- Cho KA, "Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice", Liver international : official journal of the International Association for the Study of the Liver, 31, pp.932~939 (2011)
- Jang YO, "Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis : a pilot study", Liver Int, 34, pp.33~41 (2014)
- Jang Y, "Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model", BMC Gastroenterol, 14, pp.198~ (2014)
- Dorshkind K, "Regulation of hemopoiesis by bone marrow stromal cells and their products", Annu Rev Immunol, 8, pp.111~137 (1990)
- Haynesworth SE, "Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro : effects of dexamethasone and IL-1 alpha", J Cell Physiol, 166, pp.585~592 (1996)
- Gaia S, "Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease", J Hepatol, 45, pp.13~19 (2006)
- Gordon MY, "Characterization and clinical application of human CD34+ stem", progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor, 2006, pp.24, 1822~1830
- Hu Y, "Isolation and identification of mesenchymal stem cells from human fetal pancreas", J Lab Clin Med, 141, pp.342~349 (2003)
- Martin JY, "Proliferation, differentiation, and protein synthesis of human osteoblast-like cells (MG63) cultured on previously used titanium surfaces", Clinical Oral Implants Res, 7, pp.27~37 (1996)
- Zhou P, "Human progenitor cells with high aldehyde dehydrogenase activity efficiently engraft into damaged liver in a novel model", Hepatology, 49, pp.1992~2000 (2009)
- Friedman SL, "Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies", N Engl J Med, 328, pp.1828~1835 (1993)
- Grotendorst GR, "Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation", FASEB J, 18, pp.469~479 (2004)
- Lin H, "Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases", Cell Mol Immunol, 8, pp.19~22 (2011)
- Wrana JL, "Transforming growth factor-beta signaling and cirrhosis", Hepatology, 29, pp.1909~1910 (1999)
- Choi I, "IL-6 induces hepatic inflammation and collagen synthesis in vivo", Clin Exp Immunol, 95, pp.530~535 (1994)
- Hung KS, "Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice", Biochem Biophys Res Commun, 336, pp.324~331 (2005)
- Safadi R, "Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes", Gastroenterology, 127, pp.870~882 (2004)
- Nakamura T, "Molecular cloning and expression of human hepatocyte growth factor", Nature, 342, pp.440~443 (1989)
- Michalopoulos GK, "Liver regeneration", Science, 276, pp.60~66 (1997)
- Kim WH, "Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis", Am J Pathol, 166, pp.1017~1028 (2005)
- Parekkadan B, "Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells", Biochem Biophys Res Commun, 363, pp.247~252 (2007)